This $320,597 Project Grant awarded by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) supports the development of IFNA2-LNP01, a lipid nanoparticle-encapsulated IFN2-encoding mini-plasmid DNA for the treatment of lung metastases. The two-year project aims to: 1) determine the efficacy of IFNA2-LNP01 in suppressing tumor lung metastases in vivo; and 2) evaluate the biodistribution and toxicology of IFNA2-LNP01 in vivo. This effort by awardee Chemedimmune, Inc. is expected to generate data to support a Phase II IND-enabling study of IFNA2-LNP01, a novel immunotherapy designed to activate the type I interferon signaling pathway and enhance T cell recruitment to lung metastases.
Generated 2/25/25, 5:28 AM